.Competing interests.R.S., M.S., H.G. and also A.A.R. are organizers of the 1M1M campaign.
H.G. and A.A.R. are board of directors members and R.S., M.S.
as well as A.A.R. are actually members of the clinical advisory board of N1C. A.A.R.
divulges employment by LUMC, which possesses patents on exon-skipping technology, several of which has been accredited to BioMarin and consequently sublicensed to Sarepta. As co-inventor of several of these patents, A.A.R. was allowed to an allotment of aristocracies.
A.A.R. even further reveals serving as impromptu expert for PTC Rehabs, Sarepta Therapies, Regenxbio, Dyne Therapeutics, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and Astra Zeneca. Previously 5 years, A.A.R.
also performed impromptu speaking to for Alpha Anomeric. A.A.R. likewise reports registration of the clinical boards of advisers of Eisai, Hybridize Rehabs, Muteness Therapeutics, Sarepta Rehabs, Sapreme and Mitorx.
Over the last 5 years, A.A.R. was actually additionally a clinical advisory board participant for ProQR. Pay for A.A.R.
u00e2 s consulting as well as urging activities is paid out to LUMC. In the past 5 years, LUMC additionally got audio speaker honoraria coming from PTC Therapies, Alnylam Netherlands, Italfarmaco and also Pfizer and also cashing for contract research study coming from Sapreme, Eisai, Galapagos, Synaffix as well as Alpha Anomeric. Project financing is actually obtained coming from Sarepta Rehabs as well as Entrada using unrestricted grants.
H.G. has nothing to make known in relation to the subjects dealt with in this particular manuscript. In the past 5 years, he has actually additionally obtained working as a consultant gratuity coming from UCB.
M.S. acquired consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly and also Solaxa before 5 years, all unassociated to today composition. R.S.
has nothing at all to disclose in relation to the subject matters dealt with within this document. She has obtained speaker and/or consultancy honoraria or sponsoring additions coming from Abbvie, Bial, STADA as well as Everpharma over the last 5 years.